Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Has Consensus Price Target of $19.75 According to Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $19.75.

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Satellos Bioscience in a report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th. Finally, Wells Fargo & Company set a $18.00 price objective on Satellos Bioscience in a research report on Thursday, July 9th.

Satellos Bioscience Price Performance

Shares of NASDAQ MSLE opened at $8.50 on Monday. The firm’s 50-day moving average is $9.43 and its two-hundred day moving average is $7.98. The company has a market capitalization of $180.37 million, a PE ratio of -4.43 and a beta of 1.51. Satellos Bioscience has a 12-month low of $5.30 and a 12-month high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). On average, analysts forecast that Satellos Bioscience will post -1.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC lifted its position in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 491,624 shares of the company’s stock after buying an additional 391,624 shares during the quarter. Satellos Bioscience makes up 0.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Stonepine Capital Management LLC owned about 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent quarter.

About Satellos Bioscience

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.